In human cancers, cDC1 abundance correlates with CD8+ T cell infiltration and increased overall patient survival, as well as with clinical responses to checkpoint blockade immunotherapy (Barry et al., 2018; Böttcher et al., 2018; Michea et al., 2018). This evidence concerns the gene CD8A and cancer.